Since clinicians are exploring therapeutic deintensification for HPV+ HNSCC, identifying patients with good or poor prognosis using the NF-κB Activity Classifier may be useful to guide therapeutic decisions. This evidence concerns the gene NFKB1 and head and neck squamous cell carcinoma.